n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Cancer of Prostate in 23 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Xenografts of VIP-treated PC3 prostate cancer cells in nude mice gave tumors that grew significantly faster than those in the untreated group." | 1.35 | Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398. ( Bajo, AM; Carmena, MJ; Fernández-Martínez, AB; Isabel Arenas, M; Prieto, JC; Sánchez-Chapado, M; Valdehita, A, 2009) |
| "This suggests that HF promoted prostate cancer cell growth is COX-2 dependent and this HF-COX-2 activation pathway can account for one reason of CAB therapy failure." | 1.35 | A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. ( Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S, 2008) |
| "Human prostate cancer cells LNCaP, PC-3, and CWR22Rnu1 were treated with EGCG and NS398 alone and in combination, and their effect on growth and apoptosis was evaluated." | 1.34 | Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. ( Adhami, VM; Afaq, F; Malik, A; Mukhtar, H; Pasha, FS; Saleem, M; Sarfaraz, S; Siddiqui, IA; Syed, DN; Zaman, N, 2007) |
| "Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition." | 1.33 | Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. ( Barry, JM; Beer, TM; Corless, CL; Gantner, M; Garzotto, M; Loos, J; Wagner, M; Weksler, N, 2005) |
| "Ibuprofen was significantly more effective against human prostate cancer cells in vitro than the other tested nonprescription NSAIDs." | 1.31 | Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. ( Andrews, J; Andrews, P; Djakiew, D; Krygier, S, 2002) |
| "To investigate the function of COX-2 in prostate cancer directly, we stably transfected human full-length COX-2 cDNA into LNCaP cells (LNCaP-COX-2), which express low levels of endogenous COX-2." | 1.31 | Cyclooxygenase-2 promotes prostate cancer progression. ( Fujita, H; Keller, ET; Koshida, K; Mizokami, A; Namiki, M; Takahashi, Y; Yoshimito, T, 2002) |
| "Addition of PGE(2) to PC-3ML human prostate cancer cells had no effect on HIF-1alpha mRNA levels." | 1.31 | Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. ( Dosoretz, A; Holland, JF; Kirschenbaum, A; Levine, AC; Liu, XH; Lu, M; Yao, S, 2002) |
| "DU-145 and PC-3 human prostate cancer cell lines were used to test the effect of inhibitors of PLA2, COX, or LOX on the invasion of prostate tumor cells through Matrigel in vitro using the Boyden chamber assay and fibroblast-conditioned medium as the chemoattractant." | 1.31 | Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. ( Attiga, FA; Fernandez, PM; Manyak, MJ; Patierno, SR; Weeraratna, AT, 2000) |
| "To assess the role of COX-2 in prostate cancer, we investigated whether the inhibition of COX-2 affected the proliferation of prostate cancer cells." | 1.31 | Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. ( Kamijo, T; Kitamura, T; Nagatomi, Y; Sato, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 19 (82.61) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, J | 1 |
| Wu, H | 1 |
| Shi, H | 1 |
| Pan, W | 1 |
| Yu, H | 1 |
| Zhu, J | 1 |
| John-Aryankalayil, M | 1 |
| Palayoor, ST | 3 |
| Cerna, D | 1 |
| Falduto, MT | 1 |
| Magnuson, SR | 1 |
| Coleman, CN | 3 |
| Fernández-Martínez, AB | 1 |
| Bajo, AM | 1 |
| Valdehita, A | 1 |
| Isabel Arenas, M | 1 |
| Sánchez-Chapado, M | 1 |
| Carmena, MJ | 1 |
| Prieto, JC | 1 |
| Ding, Q | 1 |
| Bai, YF | 1 |
| Wang, YQ | 1 |
| An, RH | 1 |
| Andrews, J | 1 |
| Djakiew, D | 2 |
| Krygier, S | 2 |
| Andrews, P | 2 |
| Fujita, H | 1 |
| Koshida, K | 1 |
| Keller, ET | 1 |
| Takahashi, Y | 1 |
| Yoshimito, T | 1 |
| Namiki, M | 1 |
| Mizokami, A | 1 |
| Liu, XH | 4 |
| Kirschenbaum, A | 4 |
| Lu, M | 1 |
| Yao, S | 4 |
| Dosoretz, A | 1 |
| Holland, JF | 3 |
| Levine, AC | 4 |
| Nithipatikom, K | 1 |
| Isbell, MA | 1 |
| Lindholm, PF | 1 |
| Kajdacsy-Balla, A | 1 |
| Kaul, S | 1 |
| Campell, WB | 1 |
| Tofilon, PJ | 1 |
| Wen, B | 1 |
| Deutsch, E | 1 |
| Eschwege, P | 1 |
| De Crevoisier, R | 1 |
| Nasr, E | 1 |
| Eschwege, F | 1 |
| Bourhis, J | 1 |
| Wagner, M | 1 |
| Loos, J | 1 |
| Weksler, N | 1 |
| Gantner, M | 1 |
| Corless, CL | 1 |
| Barry, JM | 1 |
| Beer, TM | 1 |
| Garzotto, M | 1 |
| Arayankalayil, MJ | 1 |
| Shoaibi, A | 1 |
| Adhami, VM | 1 |
| Malik, A | 1 |
| Zaman, N | 1 |
| Sarfaraz, S | 1 |
| Siddiqui, IA | 1 |
| Syed, DN | 1 |
| Afaq, F | 1 |
| Pasha, FS | 1 |
| Saleem, M | 1 |
| Mukhtar, H | 1 |
| Cai, Y | 1 |
| Lee, YF | 1 |
| Li, G | 1 |
| Liu, S | 1 |
| Bao, BY | 1 |
| Huang, J | 1 |
| Hsu, CL | 1 |
| Chang, C | 1 |
| Xu, ZY | 1 |
| Gao, JP | 1 |
| Sun, YH | 1 |
| Zhang, ZY | 1 |
| Ge, JP | 1 |
| Xu, CL | 1 |
| Wang, LH | 1 |
| Stearns, ME | 1 |
| Claffey, K | 1 |
| Lee, R | 1 |
| Attiga, FA | 1 |
| Fernandez, PM | 1 |
| Weeraratna, AT | 1 |
| Manyak, MJ | 1 |
| Patierno, SR | 1 |
| Johnson, AJ | 1 |
| song, X | 1 |
| Hsu, A | 1 |
| Chen, C | 1 |
| Kamijo, T | 1 |
| Sato, T | 1 |
| Nagatomi, Y | 1 |
| Kitamura, T | 1 |
| Meyer-Siegler, K | 1 |
23 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Cancer of Prostate
| Article | Year |
|---|---|
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygen | 2013 |
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumo | 2009 |
Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Hu | 2009 |
TGF-beta1 reverses inhibition of COX-2 with NS398 and increases invasion in prostate cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; D | 2010 |
Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Topics: Acetaminophen; Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Divis | 2002 |
Cyclooxygenase-2 promotes prostate cancer progression.
Topics: Animals; Blotting, Western; Cell Division; Cyclooxygenase 2; Endothelial Growth Factors; Gene Expres | 2002 |
Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.
Topics: Active Transport, Cell Nucleus; Arachidonic Acid; Catalysis; Cell Nucleus; Culture Media, Serum-Free | 2002 |
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Arachidonic Acid; Cyclooxygenase 1; Cyclooxygenase 2; | 2002 |
Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tu | 2003 |
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2003 |
Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 2005 |
Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2.
Topics: Blotting, Western; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclo | 2005 |
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Beverages; Blotting, Western; Celecoxib; Cell Line, Tum | 2007 |
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2008 |
[Nonsteroidal anti-inflammatory drug NS398 regulates the RECK gene expression in the prostate carcinoma strain DU145].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cattle; Cell Line, Tumor; Gene | 2008 |
NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
Topics: Apoptosis; Cells, Cultured; Chromatin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 1998 |
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
Topics: Androgens; Cell Hypoxia; Cobalt; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib | 1999 |
Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
Topics: Animals; Apoptosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diseas | 2000 |
Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
Topics: 3T3 Cells; Acetophenones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Cell M | 2000 |
Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.
Topics: Apoptosis; Calcium; Celecoxib; Cell Cycle; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2001 |
Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Fragmentation; Dose-Re | 2001 |
COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cyclooxygenase 2; DNA-Binding Proteins; Down | 2001 |
Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyclooxygenase 2; Cyclooxygenase | 2002 |